Ezrin peptide 1 for use in a method of treating COVID-19
AssigneePantapharm AG
InventorsThomas Nesselhut, Jan Nesselhut, Rüdiger Osmers
Life of this patent
Estimating the term…
Abstract
The present invention relates to Ezrin peptide 1 and/or an analogue thereof for use in a method of treating COVID-19 and for use in a method of treating post COVID-19 syndrome.
Claims18
A method of treating COVID-19 or post COVID-19 syndrome in a subject, comprising administering to the subject Ezrin peptide 1, wherein the Ezrin peptide 1 consists of the amino acid sequence NH2_Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu_COOH (SEQ ID NO:1).
A method of treating COVID-19 or post COVID-19 syndrome in a subject, comprising administering to the subject an analogue of Ezrin peptide 1, wherein the analogue consists of the formula (I)
- (I)
- (SEQ ID NO:
- 5)
- NH2 X1-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-
- X2-X3 COOH
- where X1, X2 and X3 are identical or different and are non-polar amino acid residues.
Dependencies are inferred from the claim text.